1. A140 IBD DASHBOARD: AN INNOVATIVE E-HEALTH PROGRAM FOR PROVIDING EQUAL ACCESS TO QUALITY CARE FOR ALL INFLAMMATORY BOWEL DISEASE PATIENTS. (1st March 2018) Authors: Sutton, R T; Wishart, E; Dhami, N; Sadowski, D; Siffledeen, J; Sauve, M; Hundal, R; Ismond, K; van Zanten, S; Huang, V Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 2 Page Start: 210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A146 THE EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS. (21st February 2022) Authors: Albino, L; Rosentreter, R; Lu, C; Siffledeen, J; Dieleman, L A; Ma, C; Baugmart, D C; Du, L; Halloran, B; Kroeker, K; Peerani, F; Wong, K Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 5(2022)Supplement 1 Page Start: 19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A171 EXPLORING PATIENT PERSPECTIVES ON A 12-WEEK, ONLINE STRESS REDUCTION INTERVENTION IN INFLAMMATORY BOWEL DISEASE. (21st February 2022) Authors: Hyde, A; Watt, M; Peerani, F; Madsen, K; Siffledeen, J; Kroeker, K; Lim, A; Tandon, P Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 5(2022)Supplement 1 Page Start: 50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn's disease by number and type of prior biologics. (30th January 2023) Authors: Peyrin-Biroulet, L; Parkes, G; Rodríguez, C; Siffledeen, J; Wright, J; Broide, E; Ford, S; Lacerda, A P; Oomen, J; Garrison, A; Berg, S; Rubin, D T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP24 Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study. (27th May 2021) Authors: Danese, S; Vermeire, S; Zhou, W; Pangan, A; Siffledeen, J; Hébuterne, X; Nakase, H; Higgins, P; Chen, M H; Sanchez-Gonzalez, Y; Huang, B; Xie, W; Liu, J; Weinreich, M; Pannaccione, R Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S022 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗